Different Groups of HDAC Inhibitors Based on Various Classifications
Histone deacetylase inhibitors (HDACs) tune the altered acetylation homeostasis by inhibiting the histone deacetylase (HDAC) activity. Thus they restore the acetylation homeostasis that is impaired in disease states. This chapter discusses the different groups of HDACi based on structural distinction and source. Further, the detailed account of various approved HDACi for treating various malignancies will be given. Notably, I will discuss the different structural components of a typical HDAC inhibitor.
- Ganai SA (2014) In silico approaches towards safe targeting of class I histone deacetylases. In: Wells RD, Bond JS, Klinman J, Masters BSS, Bell E (eds) Molecular life sciences: an encyclopedic reference. Springer New York, New York, pp 1–9Google Scholar
- Johnson NM, Farr GH 3rd, Maves L (2013) The HDAC inhibitor TSA ameliorates a zebrafish model of Duchenne muscular dystrophy. PLoS Curr 17(5). https://doi.org/10.1371/currents.md.8273cf41db10e2d15dd3ab827cb4b027
- Khan N, Jeffers M, Kumar S, Hackett C, Boldog F, Khramtsov N, Qian X, Mills E, Berghs SC, Carey N, Finn PW, Collins LS, Tumber A, Ritchie JW, Jensen PB, Lichenstein HS, Sehested M (2008) Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. Biochem J 409(2):581–589CrossRefGoogle Scholar
- Lee HZ, Kwitkowski VE, Del Valle PL, Ricci MS, Saber H, Habtemariam BA, Bullock J, Bloomquist E, Li Shen Y, Chen XH, Brown J, Mehrotra N, Dorff S, Charlab R, Kane RC, Kaminskas E, Justice R, Farrell AT, Pazdur R (2015) FDA approval: belinostat for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma. Clin Cancer Res 21(12):2666–2670CrossRefGoogle Scholar